Why It Matters
Amgen faces unprecedented legislative threats that strike at advancing stricter drug pricing controls under the Inflation Reduction Act, including international reference pricing proposals. A bipartisan coalition is pushing patent reform bills targeting the company’s strategy of delaying biosimilar competition through patent layering. Senate Democrats are investigating pharmaceutical tax practices—with Amgen explicitly named alongside Pfizer.
The stakes are enormous. Over the next decade, 118 biologics will lose patent protection, and biosimilar competition is accelerating, threatening the premium pricing that funds innovation. Pharmacy Benefit Managers controlling 80% of the market face reform legislation that could fundamentally alter manufacturer negotiations.
Amgen’s $3.55 million quarterly lobbying expenditure reflects the company’s recognition that this legislative moment is existential. The outcome will determine whether Amgen maintains current profit margins or faces structural erosion of its business model.
By the Numbers
Amgen Inc. spent $3.55 million on in-house federal lobbying during Q3 2025, maintaining consistent investment levels while supplementing with external firms including Forbes Tate Partners LLC and Akin Gump Strauss Hauer & Feld LLP.
In-house team highlights:
The 12-person roster features deep institutional access. Matthew Mark McMurray served as Chief of Staff to Rep. Anna Eshoo, then-Chair of the Energy and Commerce Health Subcommittee. Kimberly J. Love was Legislative Director for Senator Debbie Stabenow, a senior Finance Committee member. Helen R. Rhee worked as Senior Policy Counsel for the Senate HELP Committee and has represented Amgen since 2005.
Several lobbyists previously worked for industry groups PhRMA and BIO, providing coordinated industry perspective.
The Agenda
Amgen Inc. is lobbying on five primary areas reflecting core business vulnerabilities.
Drug Pricing & Medicare: Amgen is fighting the Prescription Drug Price Relief Act of 2025 (S.1818), which would impose international reference pricing, while lobbying on Inflation Reduction Act implementation and Medicare negotiation provisions.
Patent Protection: The company’s most active front involves opposing bipartisan bills including the Drug Competition Enhancement Act (S.1040) and Affordable Prescriptions for Patients Act (S.1041), which target "product hopping" and "patent thickets."
PBM Reform: Amgen tracks the Pharmacy Benefit Manager Transparency Act of 2025 (S.526), which would ban deceptive pricing and require rebate pass-throughs to health plans.
Tax Policy: The company lobbies on corporate and international tax matters amid heightened Democratic scrutiny of pharmaceutical offshore profit-shifting practices.
Supply Chain: Monitoring tariff-related issues affecting global operations while positioning domestic manufacturing investments favorably.
Broader Context
The first round of Medicare drug price negotiations takes effect in 2026, while Democrats advance more aggressive pricing controls.
The Senate Judiciary Committee has advanced bipartisan patent reform bills directly threatening Amgen’s intellectual property strategy. Over 118 biologics are expected to lose patent protection by 2034, creating a $232 billion biosimilar opportunity.
Senate Democrats have identified Amgen among companies engaged in offshore tax avoidance schemes, while Trump administration tariff threats create supply chain risks and opportunities.
Between The Lines
Amgen’s lobbying reflects defensive positioning against converging threats. The company faces escalating price controls, bipartisan patent reform targeting its competitive strategies, accelerating biosimilar competition, and tax scrutiny—all while navigating potential supply chain disruption.
The strategic deployment of veterans from key committees signals sophisticated effort to navigate an unusually hostile legislative environment where traditional industry advantages are under sustained bipartisan challenge.
Competitive Landscape
Amgen operates within coordinated industry opposition alongside PhRMA and BIO, with shared personnel creating alignment on patent protection, drug pricing, and tax policy. This coordination amplifies collective industry voice against reform efforts.
The Bottom Line
Amgen’s $3.55 million quarterly investment represents sustained defensive engagement rather than alarm-level escalation. The company manages heightened regulatory risk while maintaining traditional lobbying footprint, positioning for both defensive patent battles and offensive opportunities from domestic manufacturing advantages relative to offshore-dependent competitors.